Pharmaceuticals

Refining relabeling of pharmaceuticals

Patient safety is at the heart of drug development and licensing processes. But the duty of care does not stop at launch. Manufacturers must satisfy strict regulatory demands throughout a product’s lifecycle, including re-labeling.
1

Swiss Life Sciences – ready for R&D 2030?

Digitalization and societal shifts are pushing Life Sciences to the brink of transformation. Over the next decade, successful players will need to redefine their R&D activities in order to rein in expenses, respond to shorter product lifecycles and seize opportunities of personalized medicine.
3

Swap, don’t sell: Driving value through asset swaps

The Swiss Pharmaceuticals sector produced four USD1 billion+ deals in the first half of 2018. This is not surprising given the efforts by Pharmaceuticals and Life Sciences businesses to push new boundaries and continuously innovate.

Expanding right into Europe

Innovation is the life source of Life Sciences. But strategic and meticulous planning is key to commercial success, especially when entering a new regional market.

Das neue Heilmittelgesetz: Fluch oder Segen?

Das neue Heilmittelgesetz wurde zwar bereits vor 2 Jahren verabschiedet, in Kraft tritt es jedoch vermutlich erst am 1. Januar 2019, nach Abschluss des umfangreichen Vernehmlassungsverfahrens. Ziel und Zweck des Gesetzes ist die Regelung der Zulassung und des Vertriebs von Arzneien.
2

The decline of the traditional pharmaceutical business model

As the sector stands at a crossroads, the traditional pharmaceutical business model may become obsolete. Although it may be too late to halt its decline, it’s certainly not too late to rethink how pharmaceuticals can adapt and thrive in the face of shifting payer attitudes and patient empowerment.
8 1